The latest updates from OTCMarkets | Not displaying properly? Click here
 
October 13, 2016
 
 
New Online Equity Research Hub
 

We recently launched a new online equity research hub to connect OTCQX and OTCQB companies with equity research providers.

The OTCQX and OTCQB markets are designed for companies that are investor-focused and committed to providing information to the market.  Equity research is an essential component, offering investors an independent view of a company’s performance and a means to benchmark a company versus its sector.

With traditional coverage tied to trading activity, it can be difficult for smaller companies to receive analyst attention and for investors to access this research. Our Research Marketplace aims to bridge this gap by creating a central public repository of high-quality equity research firms and distributing this research coverage.

We are pleased to collaborate with best-in-class institutional and global equity research firms ACF Equity Research, Edison, and Sidoti & Company, LLC on this new initiative.

OTC Markets Group Introduces Online Equity Research Hub in Collaboration with ACF Equity Research, Edison and Sidoti & Company, LLCpress release

Can Paid-For Micro-Cap Research Have Value for Investors? OTC Markets is Betting It DoesEquities

OTC Markets Launches Equity Research HubCrowdfund Insider

OTC Markets Group Introduces Online ResourceBanklessTimes

Companies Can Now Buy into Sidoti's Research UniverseS&P Global Market Intelligence / SNL

 
 
 
Timely and Reliable Share Data for OTC companies
 

VStock Transfer recently became the first transfer agent to provide share data, including authorized and outstanding shares, directly to OTC Markets Group for their OTCQX, OTCQB and Pink clients as part of the Transfer Agent Verified Share Data Program. The data is now available on the company profile pages of www.otcmarkets.com, along with “Verified” logo indicating that the information is timely, reliable and from a trusted source. This information is also disseminated through data products, including the Compliance Data File, to investors and brokers.

The Transfer Agent Verified Share Data Program is an initiative designed to provide current, reliable share data to brokers and investors in securities trading on our OTCQX, OTCQB and Pink markets. As part of the program, transfer agents may deliver information to us electronically, via secure FTP or API, as often as once a day but must provide data at least once monthly.

We look forward to adding verified data from more transfer agents in the coming weeks. Learn more about the program.


 
Community Spotlight
 
Community Spotlight
 

Sacha Loiseau, President and CEO of
Mauna Kea Technologies (OTCQX: MKEAF, MKEAY)

 

“We’re essentially changing the paradigm that one has to invasively sample a tissue and wait hours or days for a lab to characterize it; we’re bringing the microscope and even the lab inside the patient.”

 

OTC Markets Group (OTCM): Tell us about your company.

Sacha Loiseau: Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time digital in vivo microscopic visualization and artificial intelligence. We’re essentially changing the paradigm that one has to invasively sample a tissue and wait hours or days for a lab to characterize it; we’re bringing the microscope and even the lab inside the patient. By doing so, we’re providing physicians and surgeons with the most relevant information they need to secure their decisions and reach better outcomes and we are helping them to connect in real-time with relevant colleagues or software algorithms to better inform their decision making process.

Our flagship product, Cellvizio, has been proven to improve diagnostic performances in a variety of applications through a large number of clinical trials in the US, Europe and Asian countries. It has received regulatory clearance for a wide range of applications in more than 40 countries, including the United States (with 12 different 510(k) clearances), Europe, Japan, China, Canada, Brazil, Russia, Turkey and Mexico. Cellvizio has already been used in over 20,000 procedures worldwide. We generate revenue from the sale of the Cellvizio system, along with recurring revenue from the use of consumable miniprobes and service contracts.

Click here to read the full interview.

OTCM: What were your major accomplishments for the last year?

Dr. Loiseau: Around one year ago, we made a strategic shift in our commercialization model designed to increase the global reach of Cellvizio and improve our financial performance. A key component of our strategy is leveraging partnerships to drive adoption of Cellvizio in specific indications or geographies where we can benefit from the expertise and resources of a partner. We have announced two new partnerships over this time period – Cook Medical for urology and Fujifilm China for gastrointestinal and pulmonology applications. While we are still in the early stages of this transition, the initial results have been more than encouraging: we returned to revenue growth in the first and second quarters of 2016, with strong growth in system shipments and reorders of our consumable miniprobes. After a difficult 2015 in which sales declined each quarter, we have shown positive metrics all around in the first half of 2016: revenue grew 11% driven by 32 Cellvizio systems sold and a 60% growth in miniprobe reorders. At the same time, our net loss in the first half of 2016 was reduced by 34% and our cash burn rate excluding financing operations was down by 47%.

Very importantly, we also strengthened our management team with the addition of a very experienced Chief Operating Officer, Pierre Forest. Under his operational leadership, the company continues to improve on its sales productivity and overall efficiency.

In September, we announced one of the most important milestones ever: the endorsement by the American Society of General Surgeons (ASGS) of Cellvizio as integral to the care of patients with Gastroesophageal Reflux Disease (GERD) and Barrett’s Esophagus. Combined with the American Gastroenterological Association’s 2015 white paper which deemed the use of Confocal Laser Endomicroscopy to be appropriate for trained physicians as an alternative to random biopsies and with the material published by the College of American Pathologists on the use of endomicroscopy for Barrett’s Esophagus surveillance, we now have three important clinical endorsements for the use of Cellvizio in the treatment of these conditions. We believe the ASGS position statement will be a catalyst for accelerated utilization of Cellvizio in U.S. anti-reflux centers and hospitals, where we already are seeing strong momentum. The addressable market is estimated at about 5 million procedures annually, an opportunity that we are fully focused on.

OTCM: What differentiates your company and what is your strategy for growth going forward?

Dr. Loiseau: To put it simply, we are the only provider of a new imaging modality that is becoming central to modern medicine and surgery. With digital in vivo and in situ fluorescence microscopic visualization (or “digital optical biopsy”) and artificial intelligence algorithms designed to assist them, physicians and surgeons finally have an easy access to the most relevant information they need.

Our technology is uniquely positioned to provide benefits for physicians and patients in diagnostic and surgical applications. In the near-term, we are focused on efficiently bringing Cellvizio to the market in as many of these potential applications as possible, leveraging partners for technology development and commercialization, along with our internal team. Longer-term, we envision a future in which the Cellvizio technology is integrated as part of the standard of care with leading medical technologies, such as data-driven robotic surgery systems.

OTCM: You are traded on Euronext Paris in France and joined the OTCQX market in the U.S. in February. What is your strategy for reaching U.S. investors?

Dr. Loiseau: The U.S. is a very important market for our business on multiple fronts. First, it represents one of the largest opportunities for Cellvizio system placements and utilization, and we are still only scratching the surface in terms of adoption with about 150 leading medical centers equipped with Cellvizio in the U.S. We are excited to see adoption grow, particularly as our partnership strategy matures and we benefit from the recent ASGS endorsement. As we gain more commercial traction in the U.S., we believe it will be inevitable that U.S. investors will be exposed to Cellvizio and the Mauna Kea investment opportunity. As we work towards these goals, we are executing a focused investor relations strategy to introduce the Mauna Kea story to investors and research analysts dedicated to the small-cap medical technology sector. We also have a robust public relations strategy to drive awareness for our customers and the Company, which will have some benefit in terms of increasing our investor community exposure.

OTCM: What else do you want investors to know about your company?

Dr. Loiseau: Today’s Cellvizio platform is the culmination of years of research, innovation, development, clinical trials and enhancements from our early commercial experience. We have learned a lot from our initial success and mistakes in the market and we are extremely excited about the impact that our technology is going to make on healthcare systems and patients lives. Mauna Kea is at a major inflection point and we are well positioned to deliver improved financial results, driven by our recent ASGS endorsement, continued positive clinical data, and the acceleration of our partnership model which should expand our global presence reach in a cost efficient manner. We are in the early stages of a strategic transition, and while results are improving, there is significant unrealized potential in our existing business that we are focused on unlocking.

Click to close.

 
 
OTCQX Video Series
 
OTCQX Video Series
 

Donald Bubar, President and CEO of Avalon Advanced Materials Inc. (TSX: AVL; OTCQX: AVLNF) speaks with Bob Power, OTC Markets VP of Corporate Services, about the company’s development of niche market metals and minerals. Watch now

 
 
 
Monthly Trade Summary - September 2016
 
 
Market Designations Number
of Securities*
Monthly
$ Volume
Monthly $ Volume
per Security
YTD $ Volume*
 
OTCQX 448 $2,670,971,615 $5,961,990 $26,637,200,518
OTCQB 938 $647,640,110 $690,447 $6,065,753,994
Pink 8,248 $11,342,281,816 $1,375,155 $102,969,869,053
Total 9,634 $14,660,893,542 $1,521,786 $135,672,823,566
 

*Data as of September 30, 2016

 
OTC Markets Blog
 
OTC Markets Blog
 

What It Means To Be a Venture Market

Not all public markets are created equal, and that diversity is a good thing.  Venture markets need to be different from traditional stock exchanges.  A venture market should provide a platform for enhancing the capital formation process of growing companies. Read more.

 
 
Blue Sky Recognition
 
Blue Sky Recognition
 

Georgia and Nebraska now recognize the OTCQX and OTCQB market for the purposes of their "Blue Sky Manual Exemption" for secondary trading. Learn more about the growing list of states that recognize our premium markets.

 
 
Crowd Invest Summit
 
Crowd Invest Summit
 

OTC Markets Group is pleased to sponsor the inaugural Crowd Invest Summit, a new conference connecting everyday Americans with crowdfunded investment opportunities.

Companies interested in learning more about the crowdfunded IPOs from preeminent authorities in the space are encouraged to attend the event.  Companies may also sign up as exhibitors and present their investment opportunities directly to potential investors under the new crowdfunding regulations of the JOBS Act Title II, Title III (Regulation CF) and Title IV (Regulation A+).

 

Where: Los Angeles, CA  |  When: December 7-8, 2016

Discount Code for OTC Markets Companies (30% off): OTC30

More Information: https://www.crowdinvestsummit.com/

 
 
 
Events
 

The Crowdfunding Conference 2016 – New York, NY (October 6-7, 2016)

5th Annual Global Crowdfunding Convention – Las Vegas, NV (October 15-17, 2016)

The MicroCap Conference – Philadelphia, PA (October 24-25, 2016)

Securities Transfer Association Annual Meeting – Naples, FL (October 25, 2016)

Bank Executive & Board Compensation Conference – Amelia Island, FL (October 25-26, 2016)

Sidoti & Company 2016 Emerging Growth Convention – New York, NY (Nov. 1, 2016)

Baruch Financial Markets Conference – New York, NY (Nov. 1, 2016)

OTCQB Executive Forum: Maximizing Your Market Value – New York, NY (Nov. 2, 2016)

AdTech Panel: How Crowdfunding is Empowering New Business – New York, NY (Nov. 3, 2016)

Regulation A+ Bootcamp – New York, NY (Nov. 10, 2016)

Global Alternative Funding Forum – Los Angeles, CA (Nov. 11, 2016)

2016 STANY International Reception and Holiday Party – New York, NY (Nov. 17, 2016)

IR Society: Best Practice Awards Dinner – London, UK (Nov. 22, 2016)

LD Micro – Los Angeles, CA (Dec. 6-8, 2016)

Crowd Invest Summit – Los Angeles, CA (Dec. 7-8, 2016)

Please contact events@otcmarkets.com for more information.

 
OTCQX Virtual Investor Conference
 
OTCQX Virtual Investor Conference - View On Demand
 

View the webcast presentations by OTCQX Resource & Energy companies and download annual reports, investor kits, surveys and other information in a virtual "trade booth." Watch the Archived Presentations

 
 
Light up the Market
 
Light up the Market
 

Follow us on Twitter at @OTCMarkets

Antibe Therapeutics (OTCQX: ATBPF)

Grupo Financiero Banorte, S.A.B. De C.V. (OTCQX: GBOOY, GBOOF)

Neurovive Pharmaceutical (OTCQX: NEVPF)

Thin Film Electronics ASA (OTCQX: TFECY, TFECF)

TOMI Environmental Solutions, Inc. (OTCQX: TOMZ)

Turkiye Garanti Bankasi A.S. (OTCQX: TKGBY, TKGBF)

 
 
 
New OTCQX and OTCQB Companies
 

Welcome to the companies that joined the OTCQX Best Market and the OTCQB Venture Market in September.

The OTCQX Best Market

Boston Omaha Corporation (OTCQX: BOMN)
Golden Predator Mining Corp (OTCQX: NTGSF)
TOMI Environmental Solutions, Inc. (OTCQX: TOMZ)


The OTCQB Venture Market

Canadian Zeolite Corp. (OTCQB: CNZCF)
Centenera Mng Corp. (OTCQB: CTMIF)
China Gewang Biotechnology, Inc. (OTCQB: CGWB)
eBizware, Inc. (OTCQB: EBZW)
Fellazo Corp. (OTCQB: FLLZ)
Glori Energy Inc. (OTCQB: GLRI, GLRIW)
Hammer Fiber Optics Holdings Corp. (OTCQB: HMMR)
Hemostemix Inc. (OTCQB: HMTXF)
Imaging3, Inc. (OTCQB: IGNG)
JA Energy (OTCQB: JAEN)
K92 Mining Inc. (OTCQB: KNTNF)
Leading Edge Materials Corp. (OTCQB: LEMIF)
Makh Group Corp. (OTCQB: MKKH)
Millennial Lithium Corp. (OTCQB: MLNLF)
Patriot Berry Farms, Inc. (OTCQB: PBFI)
Peloton Minerals Corporation (OTCQB: PMCCF)
Petrolia Energy Corp. (OTCQB: BBLS)
ProGreen US, Inc. (OTCQB: PGUS)
Rasna Therapeutics, Inc. (OTCQB: RASP)
Stealth Technologies, Inc. (OTCQB: STTH)
Sun BioPharma, Inc. (OTCQB: SNBP)
Terafox Corp. (OTCQB: TRFX)
Uni Line Corp. (OTCQB: ULNV)
West Red Lake Gold Mines, Inc. (OTCQB: RLGMF)